AI Prospecting for Bristol-Myers Squibb
Company data:
Company size:
34021 employeesWebsite URL:
https://www.bms.comIndustry
PharmaceuticalsHeadquarters:
430 E. 29th Street, 14th Floor, New York, NY 10016, United StatesInvestment round:
NYSE: BMYARR:
$47 billionKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Bristol-Myers Squibb
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Bristol Myers Squibb will present data from over 130 studies at the 2024 ASCO and EHA meetings, covering 25 cancer types and blood disorders, highlighting new pivotal data, long-term impact of existing medicines, and emerging science in immuno-oncology, targeted therapy, and other modalities[1]. The FDA has set a PDUFA goal date of December 29, 2024, for the Biologics License Application of subcutaneous nivolumab (Opdivo) co-formulated with hyaluronidase, based on the Phase 3 trial CheckMate-67T[2].
Bristol Myers Squibb will present significant data at the 2024 ASCO Genitourinary Cancers Symposium, including results from the Phase 3 CheckMate-67T trial on a subcutaneous formulation of Opdivo, four-year data from CheckMate-9ER, and eight-year data from CheckMate-214 for advanced renal cell carcinoma. Additionally, the company will disclose clinical outcomes from a Phase 1 trial of its androgen receptor ligand-directed degrader, BMS-986365, in metastatic castration-resistant prostate cancer[1].
Bristol Myers Squibb will present significant data at the 2024 ASCO Genitourinary Cancers Symposium, including results from the Phase 3 CheckMate-67T trial on a subcutaneous formulation of Opdivo, four-year data from CheckMate-9ER, and eight-year data from CheckMate-214 for advanced renal cell carcinoma. The company will also disclose clinical outcomes from a Phase 1 trial of its androgen receptor ligand-directed degrader, BMS-986365, in metastatic castration-resistant prostate cancer[1].
Open job positions at Bristol-Myers Squibb
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
